Sagimet Biosciences Inc. SGMT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +67.57%
- 1 year
- +21.87%
- Open
- 10.41
- Prev close
- 10.43
- Mkt cap
- 703.41M
- Vol
- 989.15K
- Avg vol
- 1.35M
- EPS
- -1.27
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.82
- High
- 10.54
- Forward P/E
- -1.40
- Beta
- 0.00
- Short ratio
- 1.37
- Inst. own
- 66.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 5.28
- 200-d avg
- 4.27
- 1y target
- 29.14
News
3 days ago globenewswire.com
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key…
1 week ago zacks.com
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
-
1 week ago benzinga.com
Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner…
1 week ago globenewswire.com
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner…
1 week ago seekingalpha.com
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
Sagimet Biosciences pivots denifanstat to acne, with robust Phase 3 data and a fully funded U.S. registrational trial underway. SGMT trades below cash value, presenting an asymmetric risk/reward…
2 weeks ago defenseworld.net
Applied Dna Sciences (NASDAQ:BNBX) & Sagimet Biosciences (NASDAQ:SGMT) Head to Head Comparison
Sagimet Biosciences (NASDAQ: SGMT - Get Free Report) and Applied Dna Sciences (NASDAQ: BNBX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
2 weeks ago zacks.com
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street…
-
3 weeks ago benzinga.com
Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11
52-week clinical results from the Phase 3 ASC40-304 open-label extension of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd.…
3 weeks ago globenewswire.com
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the…
3 weeks ago defenseworld.net
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Reaffirmed as “Buy” by HC Wainwright
Sagimet Biosciences (NASDAQ: SGMT - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
4 weeks ago defenseworld.net
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Sagimet Biosciences (NASDAQ: SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN,…
4 weeks ago marketbeat.com
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Sagimet Biosciences NASDAQ: SGMT said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN,…
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.
1 month ago globenewswire.com
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional…
-
1 month ago benzinga.com
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38
Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.
-
1 month ago benzinga.com
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.
1 month ago seekingalpha.com
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
1 month ago benzinga.com
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet Biosciences Inc. (NASDAQ:SGMT) reported 52-week data from a Phase 3 trial evaluating denifanstat for moderate to severe acne vulgaris.
1 month ago benzinga.com
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.
1 month ago defenseworld.net
Sagimet posts 52-week denifanstat acne data
What happened Sagimet Biosciences Inc. (NASDAQ: SGMT) said denifanstat produced a 57.8% treatment success rate after up to 52 weeks in patients with moderate to severe acne. The company said the…
-
1 month ago benzinga.com
Sagimet Biosciences Prices $115M Offer Of Shares And Warrants At $10.00/Unit
Underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so choose, in lieu of shares of Series A common stock, pre-funded…
1 month ago globenewswire.com
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional…
-
1 month ago benzinga.com
Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink
Effective September 30, 2026, the Company suspended and terminated the prospectus supplement (the "ATM Prospectus Supplement") related to the Company’s Series A common stock, par value $0.0001 per…
-
1 month ago benzinga.com
Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE, Including Investigator's Global Assessment Success With A Response Rate Of 57%, 72% Reduction In Total Lesions, And 77% Reduction In Inflammatory Lesions, And Was Generally Well-Tolerated, With No Adverse Event-Related Permanent Discontinuations
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive…
1 month ago globenewswire.com
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients Denifanstat showed…
1 month ago globenewswire.com
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional…
-
1 month ago benzinga.com
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.
1 month ago benzinga.com
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.
-
1 month ago benzinga.com
Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18
Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.
-
1 month ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.
1 month ago benzinga.com
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
2 months ago globenewswire.com
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional…
2 months ago defenseworld.net
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten analysts that are currently covering the company, Marketbeat.com…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
-
2 months ago benzinga.com
Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026
All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2026,with first patient to be enrolled shortly afterFOSTER CITY, Calif., Aug. 25, 2026 (GLOBE…
2 months ago globenewswire.com
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE…
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and raises the price target from $12 to $29.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $49 to $56.
-
2 months ago benzinga.com
Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 18.75 percent increase over losses of…
-
4 months ago benzinga.com
Sagimet Biosciences Added To Broad-Market Russell 3000 Index And Small-Cap Russell 2000 Index
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the…
4 months ago benzinga.com
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.
-
5 months ago benzinga.com
UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults
https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-associated-steatohepatitis-mash-in-adults
-
5 months ago benzinga.com
Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased
Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trialPhase 1 data show rapid…
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $12
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $35 to $12.
-
5 months ago benzinga.com
Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 41.07 percent increase over losses of…
-
6 months ago benzinga.com
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $49
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $28 to $49.
-
6 months ago benzinga.com
Guggenheim Maintains Buy on Sagimet Biosciences, Lowers Price Target to $25
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27 to $25.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session